Abstract: The present invention provides a self-healing ceramic material with reduced porosity and a method for preparing the same. The self-healing ceramic material comprises the following components by volume: 60-85 parts by volume of Al2O3, 10-20 parts by volume of TiN, 10-20 parts by volume of TiSi2, 0.1-1 parts by volume of MgO, and 0.1-1 parts by volume of Y2O3. Wherein, Al2O3 serves as a matrix, TiN and TiSi2 act as repair agents, and MgO and Y2O3 function as sintering aids. The repair function is realized by adding TiN and TiSi2, which have repair capabilities, to the ceramic matrix, enabling the ceramic material to heal cracks. TiN plays the main role of repair function, and TiSi2 assists in the repair and helps reduce the formation of surface pores.

Abstract: A method of laser-curing and forming a honeycomb diamond grinding block made from fine-grained diamonds and a ceramic binding agent is provided. The method includes preparing a slurry, where components of the slurry, by mass ratios, include: 20-21 parts of photosensitive resin; 34.5-37 parts of aluminum-oxide powder; 4-5.5 parts of fine-grained diamond powder; 0.04-0.1 parts of a photoinitiator; a range of particle sizes of the fine-grained diamond powder is 6-8 ?m; stirring the slurry to allow all components in the slurry to be fully mixed with each other to obtain a first printing material; feeding the first printing material into a light-curing printer to perform light-curing 3D printing to obtain a precursor of a finished product; and performing, by a high-temperature furnace, a degreasing operation and a high-temperature sintering treatment on the precursor to obtain the finished product of the honeycomb diamond grinding block.

Abstract: The present application relates to an iron impregnated biochar and its use as a fertilizer. The iron impregnated biochar of the present application has a ratio of iron (III) to iron (II) ranging from 5:1 to 10:1. The biochar may be produced by a method including treating the biomass with an iron (II) ion solution, pyrolyzing the iron (II)-treated biomass in an oxidative environment and recovering the biochar product from the pyrolyzed iron (II)-treated biomass.

Abstract: The present invention relates to increasing and/or maintaining nitrogen content in soil by administration of nitrogen sources particles coated with urease inhibitors. In one embodiment, urease inhibitors are dispersed in an improved organo liquid delivery system at concentration levels of 60-95%. In another embodiment, urease inhibitors were applied in a non-aqueous, organo liquid delivery system coating nitrogen sources particles utilizing simple blending equipment at temperatures of 20°-70° C. Another embodiment discloses dry, flowable nitrogen sources coated with a urease inhibitor which can be administered directly to the soil, to a dry natural and/or a manmade fertilizer or to a liquid fertilizer which provides for the reduction of nitrogen loss from the soil. In another embodiment, a composition of urea and <0.2% dimethyl sulfoxide improves the crush resistance of the urea particles.

Abstract: A method for manufacturing a hydrocarbon compound from carbon dioxide, said method including: (a) a step of preparing an absorption-conversion catalyst that includes an oxide carrier, a first component supported on the oxide carrier and including at least one type of metal selected from the group consisting of alkali metals and alkaline earth metals, and a second component supported on the oxide carrier and including at least one type of metal selected from the group consisting of Ni, Fe, Co, Cu, and Ru; (b) a step of bringing the absorption-conversion catalyst and a carbon dioxide-including gas into contact under higher pressure than atmospheric pressure, and causing the carbon dioxide to be stored in the absorption-conversion catalyst; and (c) a step of bringing the absorption-conversion catalyst that has the carbon dioxide stored therein and a reducing gas into contact under higher pressure than atmospheric pressure, and obtaining the hydrocarbon compound.

Abstract: A method of producing a hydrofluoroolefin includes reacting a chlorofluoroolefin that is represented by Formula (I) or Formula (II) and that has 8 or less carbon atoms with a hydrogen molecule, in the presence of an intermetallic compound containing at least one first metal that is selected from the group consisting of palladium, platinum, rhodium, copper and iridium, and containing a second metal that is different from the first metal, to obtain a hydrofluoroolefin in which a hydrogen atom is substituted for at least a chlorine atom represented by Cl among chlorine atoms contained in Formula (I) or Formula (II).

Abstract: To provide a novel arylamine compound with a low refractive index. The provided arylamine compound includes at least one aromatic group. The aromatic group includes a first benzene ring, a second benzene ring, a third benzene ring, and at least three alkyl groups. The first benzene ring, the second benzene ring, and the third benzene ring are directly bonded in this order. The first benzene ring is bonded to nitrogen of amine. The first benzene ring may further include a substituted or unsubstituted phenyl group. The second benzene ring or the third benzene ring may further include an alkylated phenyl group. Each of first positions and third positions of two or more of the first to third benzene rings is independently bonded to another benzene ring, a benzene ring of the alkylated phenyl group, any of the at least three alkyl groups, or the nitrogen of the amine.

Abstract: The invention relates to a method for recovering a diisocyanate which is solid at room temperature from a distillation residue from a process for producing the diisocyanate, comprising the following steps: (i) mixing the distillation residue with a bitumen such that a mixture is obtained which contains 70 to 90 wt % of the distillation residue and 10 to 30 wt % of the bitumen, each in relation to the mixture, (ii) distilling the mixture in a thin-film evaporator or a falling film evaporator to obtain a sump discharge and a gaseous product stream, (iii) condensing the gaseous product stream and obtaining a solid containing the diisocyanate which is solid at room temperature. The invention further relates to the use of a thin-film evaporator or falling film evaporator, to a composition containing the diisocyanate which is solid at room temperature, and to a method for producing an elastomer from this composition and to the elastomer itself.

Abstract: The disclosure pertains to urea production with, in series, an MP carbamate condenser for condensing at least urea synthesis section off-gas, gas/liquid separation giving a gas stream and a liquid stream, and a second carbamate condenser receiving off-gas from melamine production and said liquid stream.

Abstract: An alcohol production method in which an alcohol is produced from a carbonyl compound, the method including producing an alcohol by using a catalyst, the catalyst including a metal component including rhenium having an average valence of 4 or less and a carrier supporting the metal component, the carrier including zirconium oxide. A catalyst for producing an alcohol by hydrogenation of a carbonyl compound, the catalyst including a carrier including zirconium oxide and a metal component supported on the carrier, the metal component including rhenium having an average valence of 4 or less.

Abstract: A CO2 conversion device reacts CO2 and hydrogen as raw materials to be converted to methanol or dimethyl ether, in which a methanol synthesis catalyst and a methanol conversion catalyst are disposed with the separation membrane, and methanol and water are produced from CO2 and hydrogen by the methanol synthesis catalyst disposed on a high pressure side via the separation membrane, and then the produced methanol and water from a reaction system containing CO2 and hydrogen are selectively subjected to membrane-permeation through the separation membrane, and a mixture of methanol, dimethyl ether, and water is obtained by the methanol conversion catalyst disposed on a low pressure side via the separation membrane.

Abstract: Use of diverse biomass feedstock in a process for the recovery of target C5 and C6 alditols and target glycols via staged hydrogenation and hydrogenolysis processes is disclosed. Particular alditols of interest include, but are not limited to, xylitol and sorbitol. Various embodiments of the present invention synergistically improve overall recovery of target alditols and/or glycols from a mixed C5/C6 sugar stream without needlessly driving total recovery of the individual target alditols and/or glycols. The result is a highly efficient, low complexity process having enhanced production flexibility, reduced waste and greater overall yield than conventional processes directed to alditol or glycol production.

Abstract: The present invention relates to a new process for the production of retinal or hydrogenated form of retinal.

Abstract: A process for the preparation of perhaloacyl peroxides from perhaloacyl halides which is performed in the presence of a hydrofluoroether as the solvent.

Abstract: The present invention provides a process for preparing a dimethylcyclobutane compound of the following general formula (1A), the process comprising reacting a dimethylcyclobutanone compound of the following general formula (2) with a phosphonic ester compound of the following general formula (3) to produce an unsaturated ester compound of the following general formula (4), having a dimethylcyclobutane ring, and subjecting the unsaturated ester compound (4), having a dimethylcyclobutane ring, to a reduction reaction to produce the dimethylcyclobutane compound (1A).

Abstract: Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

Abstract: The present invention relates to a new process of production of menaquinone 4, which is also known as vitamin K2.

Abstract: Modifying agents for polyolefin resin films include a partial ester of a tri- to hexahydric polyol with a straight chain aliphatic carboxylic acid having 8 to 22 carbon atoms. The partial ester contains 70% by mass or more in total of monoesters and diesters. The mass ratio of the monoester content to the diester content is monoester/diester mass=30/70 to 86/14. This modifying agent for polyolefin resin films is applied to a polyolefin resin film in which the content of a diethanolamine compound having an alkyl group or alkenyl group having 8 to 22 carbon atoms or a diethanolamide compound having an alkyl group or alkenyl group having 8 to 22 carbon atoms is 0.02% by mass or less, and the content of an alkylsulfonic acid alkali metal salt is 0.004% by mass or less.

Abstract: The first object of the invention is the compound of general formula (I) or pharmaceutically acceptable salts thereof. A second object of the invention is the use of compounds described by general formula (I) as active ingredient in pharmaceutical compositions for the treatment of epileptic seizures or neuropathic pain or migraine.

Abstract: An object of the present invention is to provide an agent for enhancing fertilization function of a mammal sperm, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient, and a method for enhancing fertilization function of a mammal sperm and a method for preparing a mammal fertilized egg, which use a low molecular compound which can be produced relatively easily and inexpensively. An agent comprising one or more compounds selected from the group consisting of compounds of the following formula (I0), formula (II), and formula (III), and physiologically acceptable salts thereof when R3 is OH is used as an agent for enhancing fertilization function of a mammal sperm.

Abstract: A solution of extracted psychoactive alkaloids is obtained from psychoactive organisms or an existing extract using a neutral or acidic solvent. Acid extraction of psychoactive compounds from psychoactive organisms results in the dephosphorylated form of psychoactive alkaloids. The solution is basified to deprotonate the alkaloids. It is then subjected to a liquid-liquid extraction with a water-immiscible solvent. The resulting psychoactive organic layer is then subjected to a second liquid-liquid extraction with weakly acidic water. The resulting psychoactive aqueous layer is then dried to form a powder with the psychoactive alkaloid in a conjugate salt form. The powder may be standardized to a desired concentration of psychoactive alkaloid by the addition of an excipient. Alternatively, the standardization may be carried out on the psychoactive aqueous phase. Obtaining the psychoactive alkaloid in the conjugate salt form reduces the amount of non-psychoactive components included in the final extract.

Abstract: Novel 1,4-disubstituted piperidine derivatives, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 1,4-disubstituted piperidine derivatives compounds, identified as PDE5 inhibitors, are useful for the treatment of erectile dysfunction.

Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Abstract: The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.

Abstract: Compounds provided are racemic, non-racemic or substantially enantiomerically pure dimers or salts or solvates thereof of formula: where: W and W? are S or NR1, or —W—CO— or —W—CO— is —CH?CH—, where each R1 is hydrogen or an alkyl group having 1 to 3 carbon atoms; R and R? are hydrogen or an straight-chain or branched alkyl group having 1-3 carbon atoms; R3 and R?3 are hydrogen or a C1-C3 alkyl; X1, X?1, X2 and X?2 are optionally-substituted straight-chain or branched alkyl groups having 3-8 carbon atoms, optionally-substituted cycloalkyl groups having 3-12 carbon atoms; optionally-substituted aryl, optionally-substituted heteroaryl, optionally-substituted heterocycyl, optionally-substituted cycloalkylalkyl, optionally-substituted arylalkyl, optionally-substituted heteroarylalkyl and optionally-substituted heterocycylalkyl groups and L1, L?1 and L2 are divalent chemical moieties. Dimers are employed to modulate quorum sensing and to thus inhibit virulence in Staphylococcus bacteria.

Abstract: The present invention relates to a non-fullerene acceptor compound containing benzoselenadiazole, and organic optoelectronic devices comprising the same.

Abstract: A method is provided of preparing a compound of formula II: where: R1 and R2 are independently selected from —CH2OR?, —CHO, —COOR? and —H, provided that R1 and R2 are not both —H; and R? is selected from —H and C1-6 hydrocarbyl groups, from a compound of formula I: the compounds of formulas I and II being optionally in the form of a salt. The method comprises dehydrating the compound of formula I at: a pH in the range of from 0 to 6 or 8 to 11.5; and a temperature in the range of from 10 to 80° C. The method is particularly useful for synthesizing substituted furans from compounds derived from sugars.

Abstract: Disclosed are methods for synthesizing cannabielsoin (CBE) and or analogs thereof. In particular, the present disclosure provides methods for synthesizing CBE or analogs thereof comprising steps of providing a cannabinoid composition that comprises cannabidiol (CBD) or analogs thereof; combining the cannabinoid composition with an agent comprising a ketone functional group; and contacting the cannabinoid composition with an oxidizing agent or exposing the cannabinoid composition to electromagnetic radiation.

Abstract: The present disclosure relates to a method for preparing a compound of formula (I). In the compound of formula (I), n may be 0 to 5 and each of R1, R2, R3, and R4 may be independently selected from the group consisting of H, —O-Alkyl, halo, alkyl, —CN, or —NO3.

Abstract: Described herein is a compound of formula (I) in the form of any one of its stereoisomers or as a mixture thereof, and wherein R1 represents a hydrogen atom, a C1-3 alkyl group or C2-3 alkenyl group; X represents an oxygen atom when R2 represents a C1-4 alkyl group or C2-4 alkenyl group or X represents a CH2-O group when R2 represents a C2-4 alkenyl group or a MeC?O group. The use as a perfuming ingredient of this compound and this compound as part of a perfuming composition or of a perfuming consumer product are also described.

Abstract: Disclosed herein, inter alia, are trioxolane compounds and methods of using the same for treatment and detection of diseases.

Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

Abstract: The present disclosure provides compounds of the formula pharmaceutical compositions, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.

Abstract: Activators of Kv3.1 and/or Kv3.2 channels which are therapeutically useful in the treatment of cognitive dysfunction and the negative symptoms which are associated with central nervous system disorders such as schizophrenia, Alzheimer's disease, Tourette's syndrome, autism, dementia, epilepsy and other disorders where gamma oscillations are dysfunctional are provided. The activators include substituted N-heteroaryl compounds.

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

Abstract: Disclosed are a 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof. Specifically disclosed is a compound or a pharmacologically acceptable salt thereof or a prodrug thereof. The compound has the structure of formula I. The compound or the pharmacologically acceptable salt thereof or the prodrug thereof has excellent inhibition to transient receptor potential (TPR) channel proteins, and has good therapeutic effect on diseases related to the TPR channel proteins.

Abstract: The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

Abstract: Described herein are heterocycle substituted pyridine derivative antifungal agents and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

Abstract: The invention relates to a kinase inhibitor, in particular an inhibitor of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitor of the invention displays, eg functional and ADMET properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise the kinase inhibitor, including those formulated for oral administration, such as in unit dose form that comprise particular ranges or amounts of the kinase inhibitor. The kinase inhibitor or pharmaceutical composition may be used in the treatment of a proliferative disorder, such as a leukaemia or solid tumour.

Abstract: Compositions are disclosed herein that include macrocycle derivatives incorporating bridged macrocycles. Also disclosed are methods of producing and using the compositions.

Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1 to Z5, L, n, the A ring, and the B ring, are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

Abstract: Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

Abstract: The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.

Abstract: The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.

Abstract: Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation.

Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.